Entera Bio (ENTX) EBT Growth (3y) (2022 - 2026)

Entera Bio (ENTX) EBT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.34%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 40.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -1.05%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Entera Bio 186.78 Mn 182.64 Mn - -18.14%

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.14%
Dec 31, 2025 -0.61%
Sep 30, 2025 -6.11%
Jun 30, 2025 5.03%
Mar 31, 2025 11.60%
Dec 31, 2024 17.10%
Sep 30, 2024 2.17%
Jun 30, 2024 2.09%
Mar 31, 2024 3.71%
Jun 30, 2023 10.01%
Jun 30, 2022 -16.27%